Hologic has now acquired Biotheranostics, developer of two highly differentiated molecular diagnostic tests for breast and metastatic cancers – Breast Cancer Index™ (BCI) and CancerTYPE ID® (CTID).
Breast Cancer Index predicts which early-stage hormone receptor positive (HR+) breast cancer patients are likely to benefit from extended endocrine therapy and is included in clinical practice guidelines from prominent organizations including the National Comprehensive Cancer Network® (NCCN®) and the American Society for Clinical Oncology (ASCO). Terminating endocrine therapy in those patients unlikely to benefit may save healthcare dollars and reduce patient exposure to challenging side effects of therapy.
Cancer TYPE ID provides a molecular diagnosis for patients with uncertain or unknown cancers. In advanced cancer that has metastasized, it can be difficult to determine the tumor type and subtype, information that is needed to optimize treatment selection.
Both of Biotheranostics’ tests are PCR (polymerase chain reaction)-based gene expression tests that have been extensively validated in large studies in areas of oncology with critical unmet needs.